The Claim
Myostatin-binding peptides engineered with a photooxygenation catalyst inactivate myostatin selectively under near-infrared light with low phototoxicity.
What the research says
Not yet evaluated
We are still looking at what the research says.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Engineered peptides that bind to myostatin and respond to near-infrared light can turn off myostatin activity without causing significant tissue damage.
See the scientific wording
Myostatin-binding peptides engineered with a photooxygenation catalyst can be designed to inactivate myostatin selectively under near-infrared light with low phototoxicity, suggesting a novel approach to targeted protein inhibition.
A specially designed protein piece binds to a muscle-growth blocker called myostatin. When near-infrared light shines on it, the protein piece releases a burst of reactive molecules that permanently damage myostatin, so it can no longer stop muscles from growing. This only happens where the light is applied, leaving other tissues untouched.
What the research says
1 studyScientists made special tiny protein pieces that latch onto myostatin (a muscle-limiting protein) and, when hit with a safe kind of light, turn off myostatin without hurting nearby tissue. This could help treat muscle diseases.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.